Cost-effectiveness analysis of selective first-line use of biologics for unresectable RAS wild-type left-sided metastatic colorectal cancer

BACKGROUND: Evidence from a retrospective analysis of multiple large phase iii trials suggested that primary tumour location (ptl) in RAS wild-type metastatic colorectal cancer (wtRAS mcrc) might have predictive value with respect to response to drug therapies. Recent studies also show a potential p...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Curr Oncol
Egile Nagusiak: Wong, W.W.L., Zargar, M., Berry, S.R., Ko, Y.J., Riesco-Martínez, M., Chan, K.K.W.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Multimed Inc. 2019
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6821119/
https://ncbi.nlm.nih.gov/pubmed/31708653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.26.4843
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak